Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Apr;31(4):381–390. doi: 10.1111/j.1365-2125.1991.tb05550.x

Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers.

Z R Chen 1, A A Somogyi 1, G Reynolds 1, F Bochner 1
PMCID: PMC1368322  PMID: 2049245

Abstract

1. The pharmacokinetics, metabolism and partial clearances of codeine to morphine, norcodeine and codeine-6-glucuronide after single (30 mg) and chronic (30 mg 8 h for seven doses) administration of codeine were studied in eight subjects (seven extensive and one poor metaboliser of dextromethorphan). Codeine, codeine-6-glucuronide, morphine and norcodeine were measured by high performance liquid chromatographic assays. 2. After the single dose, the time to achieve maximum plasma codeine concentrations was 0.97 +/- 0.31 h (mean +/- s.d.) and for codeine-6-glucuronide it was 1.28 +/- 0.49 h. The plasma AUC of codeine-6-glucuronide was 15.8 +/- 4.5 times higher than that of codeine. The AUC of codeine in saliva was 3.4 +/- 1.1 times higher than that in plasma. The elimination half-life of codeine was 3.2 +/- 0.3 h and that of codeine-6-glucuronide was 3.2 +/- 0.9 h. 3. The renal clearance of codeine was 183 +/- 59 ml min-1 and was inversely correlated with urine pH (r = 0.81). These data suggest that codeine undergoes filtration at the glomerulus, tubular secretion and passive reabsorption. The renal clearance of codeine-6-glucuronide was 55 +/- 21 ml min-1, and was not correlated with urine pH. Its binding to human plasma was less than 10%. These data suggest that codeine-6-glucuronide undergoes filtration at the glomerulus and tubular reabsorption. This latter process is unlikely to be passive. 4. After chronic dosing, the pharmacokinetics of codeine and codeine-6-glucuronide were not significantly different from the single dose pharmacokinetics. 5. After the single dose, 86.1 +/- 11.4% of the dose was recovered in urine, of which 59.8 +/- 10.3% was codeine-6-glucuronide, 7.1 +/- 1.1% was total morphine, 6.9 +/- 2.1% was total norcodeine and 11.8 +/- 3.9% was unchanged codeine. These recoveries were not significantly different (P greater than 0.05) after chronic administration. 6. After the single dose, the partial clearance to morphine was 137 +/- 31 ml min-1 in the seven extensive metabolisers and 8 ml min-1 in the poor metaboliser; to norcodeine the values were 103 +/- 33 ml min-1 and 90 ml min-1; to codeine-6-glucuronide the values were 914 +/- 129 ml min-1 and 971 ml min-1; and intrinsic clearance was 1568 +/- 103 ml min-1 and 1450 ml min-1. These values were not significantly (P greater than 0.05) altered by chronic administration.(ABSTRACT TRUNCATED AT 400 WORDS)

Full text

PDF
381

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ADLER T. K., FUJIMOTO J. M., WAY E. L., BAKER E. M. The metabolic fate of codeine in man. J Pharmacol Exp Ther. 1955 Jul;114(3):251–262. [PubMed] [Google Scholar]
  2. AXELROD J., INSCOE J. K. Glucuronide formation of narcotic drugs in vitro and in vivo. Proc Soc Exp Biol Med. 1960 Apr;103:675–676. doi: 10.3181/00379727-103-25631. [DOI] [PubMed] [Google Scholar]
  3. Aherne G. W., Littleton P. Morphine-6-glucuronide, an important factor in interpreting morphine radioimmunoassays. Lancet. 1985 Jul 27;2(8448):210–211. doi: 10.1016/s0140-6736(85)91519-3. [DOI] [PubMed] [Google Scholar]
  4. BOYLAND E., WILLIAMS K. The biochemistry of aromatic amines. 7. The enzymic hydrolysis of aminonaphthyl glucosiduronic acids. Biochem J. 1960 Aug;76:388–396. doi: 10.1042/bj0760388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bodd E., Beylich K. M., Christophersen A. S., Mørland J. Oral administration of codeine in the presence of ethanol: a pharmacokinetic study in man. Pharmacol Toxicol. 1987 Nov;61(5):297–300. doi: 10.1111/j.1600-0773.1987.tb01822.x. [DOI] [PubMed] [Google Scholar]
  6. Brinn R., Brøsen K., Gram L. F., Haghfelt T., Otton S. V. Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol. 1986 Aug;22(2):194–197. doi: 10.1111/j.1365-2125.1986.tb05250.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chen Z. R., Bochner F., Somogyi A. Pharmacokinetics of pholcodine in healthy volunteers: single and chronic dosing studies. Br J Clin Pharmacol. 1988 Oct;26(4):445–453. doi: 10.1111/j.1365-2125.1988.tb03404.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chen Z. R., Bochner F., Somogyi A. Simultaneous determination of codeine, norcodeine and morphine in biological fluids by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1989 Jul 21;491(2):367–378. doi: 10.1016/s0378-4347(00)82854-6. [DOI] [PubMed] [Google Scholar]
  9. Chen Z. R., Reynolds G., Bochner F., Somogyi A. Direct determination of codeine-6-glucuronide in plasma and urine using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1989 Sep 1;493(2):313–324. doi: 10.1016/s0378-4347(00)82737-1. [DOI] [PubMed] [Google Scholar]
  10. Chen Z. R., Somogyi A. A., Bochner F. Polymorphic O-demethylation of codeine. Lancet. 1988 Oct 15;2(8616):914–915. doi: 10.1016/s0140-6736(88)92529-9. [DOI] [PubMed] [Google Scholar]
  11. Chen Z. R., Somogyi A. A., Bochner F. Simultaneous determination of dextromethorphan and three metabolites in plasma and urine using high-performance liquid chromatography with application to their disposition in man. Ther Drug Monit. 1990 Jan;12(1):97–104. doi: 10.1097/00007691-199001000-00018. [DOI] [PubMed] [Google Scholar]
  12. Combie J., Blake J. W., Nugent T. E., Tobin T. Morphine glucuronide hydrolysis: superiority of beta-glucuronidase from Patella vulgata. Clin Chem. 1982 Jan;28(1):83–86. [PubMed] [Google Scholar]
  13. Dayer P., Desmeules J., Leemann T., Striberni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun. 1988 Apr 15;152(1):411–416. doi: 10.1016/s0006-291x(88)80729-0. [DOI] [PubMed] [Google Scholar]
  14. Eichelbaum M., Spannbrucker N., Steincke B., Dengler H. J. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol. 1979 Sep;16(3):183–187. doi: 10.1007/BF00562059. [DOI] [PubMed] [Google Scholar]
  15. Findlay J. W., Butz R. F., Welch R. M. Codeine kinetics as determined by radioimmunoassay. Clin Pharmacol Ther. 1977 Oct;22(4):439–446. doi: 10.1002/cpt1977224439. [DOI] [PubMed] [Google Scholar]
  16. Findlay J. W., Fowle A. S., Butz R. F., Jones E. C., Weatherley B. C., Welch R. M., Posner J. Comparative disposition of codeine and pholcodine in man after single oral doses. Br J Clin Pharmacol. 1986 Jul;22(1):61–71. doi: 10.1111/j.1365-2125.1986.tb02881.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Findlay J. W., Jones E. C., Butz R. F., Welch R. M. Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics. Clin Pharmacol Ther. 1978 Jul;24(1):60–68. doi: 10.1002/cpt197824160. [DOI] [PubMed] [Google Scholar]
  18. Guay D. R., Awni W. M., Findlay J. W., Halstenson C. E., Abraham P. A., Opsahl J. A., Jones E. C., Matzke G. R. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther. 1988 Jan;43(1):63–71. doi: 10.1038/clpt.1988.12. [DOI] [PubMed] [Google Scholar]
  19. Guay D. R., Awni W. M., Halstenson C. E., Findlay J. W., Opsahl J. A., Abraham P. A., Jones E. C., Matzke G. R. Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. J Clin Pharmacol. 1987 Dec;27(12):983–987. doi: 10.1002/j.1552-4604.1987.tb05601.x. [DOI] [PubMed] [Google Scholar]
  20. Hanks G. W., Aherne G. W. Morphine metabolism: does the renal hypothesis hold water? Lancet. 1985 Jan 26;1(8422):221–222. doi: 10.1016/s0140-6736(85)92057-4. [DOI] [PubMed] [Google Scholar]
  21. Huang Y. C., Chiou W. L. Creatinine XII: comparison of assays of low serum creatinine levels using high-performance liquid chromatography and two picrate methods. J Pharm Sci. 1983 Jul;72(7):836–837. doi: 10.1002/jps.2600720736. [DOI] [PubMed] [Google Scholar]
  22. Jackson P. R., Tucker G. T., Lennard M. S., Woods H. F. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol. 1986 Nov;22(5):541–550. doi: 10.1111/j.1365-2125.1986.tb02933.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. LEVVY G. A. The preparation and properties of beta-glucuronidase. IV. Inhibition by sugar acids and their lactones. Biochem J. 1952 Nov;52(3):464–472. doi: 10.1042/bj0520464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  25. Nebert D. W., Nelson D. R., Adesnik M., Coon M. J., Estabrook R. W., Gonzalez F. J., Guengerich F. P., Gunsalus I. C., Johnson E. F., Kemper B. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA. 1989 Jan-Feb;8(1):1–13. doi: 10.1089/dna.1.1989.8.1. [DOI] [PubMed] [Google Scholar]
  26. Nomof N., Elliott H. W., Parker K. D. Actions and metabolism of codeine (methylmorphine) administration by continuous intravenous infusion to humans. Clin Toxicol. 1977 Dec;11(5):517–529. doi: 10.3109/15563657708988217. [DOI] [PubMed] [Google Scholar]
  27. Osborne R., Joel S., Trew D., Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet. 1988 Apr 9;1(8589):828–828. doi: 10.1016/s0140-6736(88)91691-1. [DOI] [PubMed] [Google Scholar]
  28. Pasternak G. W., Bodnar R. J., Clark J. A., Inturrisi C. E. Morphine-6-glucuronide, a potent mu agonist. Life Sci. 1987 Dec 28;41(26):2845–2849. doi: 10.1016/0024-3205(87)90431-0. [DOI] [PubMed] [Google Scholar]
  29. Quiding H., Anderson P., Bondesson U., Boréus L. O., Hynning P. A. Plasma concentrations of codeine and its metabolite, morphine, after single and repeated oral administration. Eur J Clin Pharmacol. 1986;30(6):673–677. doi: 10.1007/BF00608214. [DOI] [PubMed] [Google Scholar]
  30. Rogers J. F., Findlay J. W., Hull J. H., Butz R. F., Jones E. C., Bustrack J. A., Welch R. M. Codeine disposition in smokers and nonsmokers. Clin Pharmacol Ther. 1982 Aug;32(2):218–227. doi: 10.1038/clpt.1982.151. [DOI] [PubMed] [Google Scholar]
  31. Svensson J. O., Rane A., Säwe J., Sjöqvist F. Determination of morphine, morphine-3-glucuronide and (tentatively) morphine-6-glucuronide in plasma and urine using ion-pair high-performance liquid chromatography. J Chromatogr. 1982 Jul 9;230(2):427–432. doi: 10.1016/s0378-4347(00)80494-6. [DOI] [PubMed] [Google Scholar]
  32. Tucker G. T., Silas J. H., Iyun A. O., Lennard M. S., Smith A. J. Polymorphic hydroxylation of debrisoquine. Lancet. 1977 Oct 1;2(8040):718–718. doi: 10.1016/s0140-6736(77)90527-x. [DOI] [PubMed] [Google Scholar]
  33. Vaughan D. P., Beckett A. H. The influence of reducing the C7-C8 double bond of codeine to give dihydrocodeine on the relative physiological availability of the drugs in man. J Pharm Pharmacol. 1973 Dec;25(Suppl):104P–1108. [PubMed] [Google Scholar]
  34. Yoshimura H., Ida S., Oguri K., Tsukamoto H. Biochemical basis for analgesic activity of morphine-6-glucuronide. I. Penetration of morphine-6-glucuronide in the brain of rats. Biochem Pharmacol. 1973 Jun 15;22(12):1423–1430. doi: 10.1016/0006-2952(73)90320-1. [DOI] [PubMed] [Google Scholar]
  35. Yoshimura H., Oguri K., Tsukamoto H. Metabolism of drugs. LX. The synthesis of codeine and morphine glucuronides. Chem Pharm Bull (Tokyo) 1968 Nov;16(11):2114–2119. doi: 10.1248/cpb.16.2114. [DOI] [PubMed] [Google Scholar]
  36. Yue Q. Y., Svensson J. O., Alm C., Sjöqvist F., Säwe J. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol. 1989 Dec;28(6):639–645. doi: 10.1111/j.1365-2125.1989.tb03556.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Yue Q. Y., Svensson J. O., Alm C., Sjöqvist F., Säwe J. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol. 1989 Dec;28(6):629–637. doi: 10.1111/j.1365-2125.1989.tb03555.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Yue Q., von Bahr C., Odar-Cederlöf I., Säwe J. Glucuronidation of codeine and morphine in human liver and kidney microsomes: effect of inhibitors. Pharmacol Toxicol. 1990 Mar;66(3):221–226. doi: 10.1111/j.1600-0773.1990.tb00737.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES